tetanus-diphtheria + PCV13

"Tetanus-diphtheria + PCV13" refers to a vaccination approach where tetanus-diphtheria (Td) vaccine is administered alongside the 13-valent pneumococcal conjugate vaccine (PCV13), either simultaneously or sequentially.\n\nThe tetanus-diphtheria (Td) component is a toxoid vaccine that protects against tetanus and diphtheria infections. Each 0.5-mL dose of Td contains tetanus toxoid and diphtheria toxoid as active ingredients[2]. This vaccine is part of the broader class of diphtheria and tetanus toxoid-containing vaccines, which may also include pertussis components (as in DTaP or Tdap).\n\nPCV13 (also known as Prevnar 13) is a vaccine that protects against 13 strains of Streptococcus pneumoniae, which is the most common cause of middle ear infections, sepsis in children, and pneumonia in immunocompromised individuals and the elderly[3].\n\nAccording to the search results, studies have evaluated the co-administration of these vaccines. One clinical study specifically assessed whether administering the inactivated influenza vaccine (IIV4) separately from PCV13 and DTaP would reduce fever occurrence after vaccination[5]. The study found that delaying IIV4 administration by 2 weeks in children receiving DTaP and PCV13 did not reduce fever occurrence after vaccination.\n\nMultiple clinical studies evaluating concurrent administration of DTaP-based combination vaccines with a seven-valent pneumococcal conjugate vaccine found no significant immunological interference between the vaccines[4].\n\nThis combination approach is part of the recommended childhood immunization schedule, which typically includes 5 doses of diphtheria, tetanus, and acellular pertussis vaccine (DTaP) and 4 doses of pneumococcal conjugate vaccine (PCV13)[9].

Brand names

Prevnar 13Prevnar13Prevnar-13

Other names

Td + PCV13